All In Biotech

NDA 018332 · Cosette

Indocin

Indomethacin · Oral · Nonsteroidal Anti-inflammatory Drug

Last checked: Nov 19, 2026Latest source record: Nov 21, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1985

Oct 10, 1985

Approved uses

1

Original approval plus efficacy supplements

Registered trials

557

100 Phase 3, 44 recruiting

FAERS reports

13,296

10,490 serious, 1,529 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS Cardiovascular Thrombotic Events Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use [ see Warnings and Precautions ( 5.1 ) ]. INDOCIN is contraindicated in the setting of coronary artery bypass graft (CABG) surgery [ see Contraindications ( 4 ) and Warnings and Precautions ( 5.1 ) ]. Gastrointestinal Bleeding, Ulceration, and Perforation NSAIDs cause an increased risk of serious gastrointestinal (GI) adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients and patients...

What it is approved for

From the label in effect Dec 16, 2024.

INDOCIN Oral Suspension is indicated for: Moderate to severe rheumatoid arthritis including acute flares of chronic disease Moderate to severe ankylosing spondylitis Moderate to severe osteoarthritis Acute painful shoulder (bursitis and/or tendinitis) Acute gouty arthritis INDOCIN is a nonsteroidal anti-inflammatory drug indicated for: Moderate to severe rheumatoid arthritis including acute flares of chronic disease Moderate to severe ankylosing spondylitis Moderate to severe osteoarthritis Acute painful shoulder (bursitis and/or tendinitis) Acute gouty arthritis ( 1 )

Mechanism: Indomethacin has analgesic, anti-inflammatory, and antipyretic properties. The mechanism of action of INDOCIN, like that of other NSAIDs, is not completely understood but involves inhibition of cyclooxygenase (COX-1 and COX-2). Indomethacin is a potent inhibitor of prostaglandin synthesis in vitro. Indomethacin concentrations reached during therapy have produced in vivo effects. Prostaglandins sensitize afferent nerves and potentiate the action of bradykinin in inducing pain in animal models. Prostaglandins are mediators of inflammation. Because indomethacin is an inhibitor of prostaglandin...

Therapeutic areas: Pain and anesthesia

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Oct 10, 1985 Original approval · Type 3 - New Dosage Form
1 products under this application
  • INDOCIN · INDOMETHACIN 25MG/5ML · SUSPENSION, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Indomethacin" as an intervention, any sponsor and status, largest first.

All 557 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective1,432
  • fatigue1,151
  • headache1,058
  • arthralgia1,036
  • off label use1,027
  • nausea949
  • pain944
  • diarrhoea906
  • dizziness894
  • dyspnoea770
  • vomiting760
  • asthenia658

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004358
2005372
2006391
2007385
2008356
2009408
2010374
2011486
2012702
2013430
2014395
2015555
2016681
2017592
2018740
2019820
2020640
2021755
20221,010
2023867
2024884
2025742
2026352

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Indocin* (Indomethacin)

2024 spending

$527K

Beneficiaries

28

68 claims

Per beneficiary

$18,812

$225.42 per unit

View as table
YearSpending
2020$1,157,154
2021$1,727,497
2022$1,840,708
2023$1,458,672
2024$526,749

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 2,046 on PubMed

Sponsor: Cosette

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.